Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database

Conclusion: Our study provided a comprehensive evaluation of lurbinectedin’s safety profile in the post-marketing setting. In addition to the adverse events consistent with the existing clinical trials and labeling information, we have also identified an unreported signal related to tumor lysis syndrome. This finding will better guide the clinical practice of lurbinectedin and provide valuable evidence for future research.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research